MORF

Morphic Holding, Inc.

NASDAQHealthcareBiotechnologyUS

CEO

Praveen P. Tipirneni

IPO Date

2019-06-27

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

News SentimentBullish

Articles

Avg Positive

39.8%

Avg Negative

6.2%

Avg Neutral

53.8%

News Feed

Morphic Therapeutic Shares New Positive MORF-057 Data From IBD Study

Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD

Strength Seen in Morphic Holding, Inc. (MORF): Can Its 6% Jump Turn into More Strength?